CN115282232B - Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation - Google Patents
Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation Download PDFInfo
- Publication number
- CN115282232B CN115282232B CN202210947482.6A CN202210947482A CN115282232B CN 115282232 B CN115282232 B CN 115282232B CN 202210947482 A CN202210947482 A CN 202210947482A CN 115282232 B CN115282232 B CN 115282232B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 title abstract description 12
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 27
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- 241001061264 Astragalus Species 0.000 claims abstract description 23
- 210000004233 talus Anatomy 0.000 claims abstract description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 19
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 19
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 19
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 16
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 16
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 16
- 235000014066 European mistletoe Nutrition 0.000 claims abstract description 13
- 244000152640 Rhipsalis cassutha Species 0.000 claims abstract description 13
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000010298 pulverizing process Methods 0.000 claims abstract description 5
- 244000281702 Dioscorea villosa Species 0.000 claims abstract 6
- 244000182216 Mimusops elengi Species 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000009759 San-Chi Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000605445 Anemarrhena asphodeloides Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 8
- 201000008383 nephritis Diseases 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 206010018367 Glomerulonephritis chronic Diseases 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 235000002723 Dioscorea alata Nutrition 0.000 abstract description 4
- 235000007056 Dioscorea composita Nutrition 0.000 abstract description 4
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 abstract description 4
- 235000005362 Dioscorea floribunda Nutrition 0.000 abstract description 4
- 235000004868 Dioscorea macrostachya Nutrition 0.000 abstract description 4
- 235000005361 Dioscorea nummularia Nutrition 0.000 abstract description 4
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 abstract description 4
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 abstract description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 240000005717 Dioscorea alata Species 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 240000002624 Mespilus germanica Species 0.000 description 12
- 210000005084 renal tissue Anatomy 0.000 description 11
- 206010023421 Kidney fibrosis Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 210000000626 ureter Anatomy 0.000 description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 5
- 208000033679 diabetic kidney disease Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 201000002793 renal fibrosis Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000972672 Phellodendron Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000037740 Coptis chinensis Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 241000316342 Taxillus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 241000746375 Andrographis Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000096284 Gynochthodes officinalis Species 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating kidney diseases, an extract, a preparation method, application and a preparation, wherein the traditional Chinese medicine composition contains mistletoe, medlar, american ginseng, astragalus, yam rhizome, phellodendron bark, rhizoma anemarrhenae and pseudo-ginseng; the extract is prepared by extracting the traditional Chinese medicine composition; the preparation method comprises pulverizing the raw materials of the Chinese medicinal composition; the application is the application of the traditional Chinese medicine composition and/or the extract in preparing a preparation for treating kidney diseases; the preparation comprises the traditional Chinese medicine composition and/or the extract. The traditional Chinese medicine composition disclosed by the invention is prepared by selecting and matching eight traditional Chinese medicines of mistletoe, medlar, american ginseng, astragalus, yam rhizome, phellodendron bark, rhizoma anemarrhenae and pseudo-ginseng, and utilizing the synergistic effect of the four raw materials of astragalus, yam rhizome, phellodendron bark and pseudo-ginseng, has the effects of protecting kidney and delaying the progress of kidney diseases through anti-inflammatory treatment, and remarkably improves the clinical symptoms and manifestations of common kidney diseases such as acute and chronic nephritis, chronic kidney disease and renal failure, and is safe and free from toxic and side effects.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compositions, and in particular relates to a traditional Chinese medicine composition for treating kidney diseases, an extract, a preparation method, application and a preparation.
Background
Kidney disease is a serious disease, and is mainly characterized by difficult cure and easy recurrence. At present, hormone and immunosuppression medicines are mostly selected in clinical treatment of kidney diseases, but most patients are treated by traditional Chinese medicine due to obvious side effects of the medicines.
CN1166379C discloses a medicament for treating kidney diseases, which is prepared from Cordyceps sinensis, hairy antler, ginseng, scorpion, centipede, morinda officinalis, corn, tripterygium glycosides, medlar, medicated leaven and red bean as raw materials according to a certain proportion into different dosage forms such as capsules.
CN101164593a discloses a traditional Chinese medicine oral liquid for treating kidney diseases. The traditional Chinese medicine oral liquid is prepared from the following medicines in parts by weight: 5g of coptis chinensis, 12 g of scutellaria baicalensis, 35 g of astragalus membranaceus, 10 g of cortex phellodendri, 5g of rheum officinale, 13 g of prepared rehmannia root, 12 g of eucommia ulmoides, 15 g of fructus forsythiae, 8 g of common andrographis herb, 13 g of dyers woad leaf, 18 g of sculellaria barbata, 10 g of cassia twig, 18 g of cordate houttuynia, 10 g of medlar, 8 g of radix ophiopogonis, 12 g of white paeony root, 12 g of bighead atractylodes rhizome, 9 g of rhizoma alismatis, 15 g of poria cocos, 15 g of semen plantaginis, 18 g of desmodium and 15 g of cogongrass rhizome. The invention has the advantages of uniform curative effect on various nephritis and nephrotic syndrome, and no toxic or side effect.
CN103316101a discloses a traditional Chinese medicine for treating diabetic nephropathy and a preparation method thereof, the traditional Chinese medicine for treating diabetic nephropathy is prepared from the following traditional Chinese medicinal materials in parts by weight: 6-15 parts of fenugreek, 6-15 parts of astragalus, 3-8 parts of epimedium, 3-8 parts of fructus psoraleae, 3-8 parts of dogwood, 1-5 parts of rheum officinale, 3-8 parts of cinnamon and 2-6 parts of coptis chinensis. The invention plays a certain role in treating type 1 diabetic nephropathy by reducing the urine protein of a rat with diabetic nephropathy and inhibiting the interstitial fibrosis of the renal tubules in a dose-dependent manner, and the role is equivalent to benazepril hydrochloride tablets but stronger than the kidney qi pill with golden-deficiency.
At present, the traditional Chinese medicine for treating kidney diseases has various formulas and unsatisfactory treatment effects. Renal fibrosis is a key pathological process in the development of kidney disease, and therefore, searching for a safe and effective treatment method is a current research hotspot.
Glycolipid metabolism disorder (Glucolipid Metabolic Disorders, GLMD) is a complex disease characterized by disorder of carbohydrate and lipid metabolism, and is involved in various factors such as genetics, environment, spirit, etc. The core mechanism mainly comprises: neuroendocrine disorders, insulin resistance, oxidative stress, inflammation, and intestinal dysbacteriosis, among others. The clinical characteristics mainly comprise single or complications such as hyperglycemia, blood lipid disorder, nonalcoholic fatty liver, overweight, hypertension, atherosclerosis and the like. The applicant team provides a comprehensive integrated treatment strategy of a liver regulating, liver opening, turbid resolving method aiming at the concept of glycolipid metabolic diseases.
Under the guidance of the theory of regulating liver, starting and eliminating turbid pathogen, the applicant develops a traditional Chinese medicine composition aiming at diabetic nephropathy caused by glycolipid metabolic disorder. The research shows that the traditional Chinese medicine composition can effectively treat kidney fibrosis, and has important significance for clinical application of common kidney diseases such as acute and chronic nephritis, chronic kidney disease, renal failure and the like.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating kidney diseases, an extract, a preparation method, application and a preparation, wherein the traditional Chinese medicine composition is prepared by carefully selecting eight traditional Chinese medicines under the guidance of a theory of liver regulating, liver activating and turbidity resolving, and the traditional Chinese medicine composition has the effects of protecting kidney and delaying the kidney disease process by utilizing the synergistic interaction of four raw materials of astragalus, yam rhizome, phellodendron bark and pseudo-ginseng, preventing and treating kidney fibrosis through anti-inflammation, and remarkably improves the clinical symptoms and manifestations of common kidney diseases such as acute and chronic nephritis, chronic kidney disease, renal failure and the like, and is safe and free from toxic and side effects.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a Chinese medicinal composition for treating nephropathy comprises herba Taxilli, fructus Lycii, radix Panacis Quinquefolii, radix astragali, rhizoma Dioscoreae Septemlobae, cortex Phellodendri, rhizoma anemarrhenae and Notoginseng radix.
Preferably, the traditional Chinese medicine composition for treating kidney diseases comprises the following components in parts by weight: 5-20 parts of mistletoe, 10-20 parts of medlar, 5-15 parts of American ginseng, 10-30 parts of astragalus, 5-20 parts of yam rhizome, 5-15 parts of amur corktree bark, 10-30 parts of rhizoma anemarrhenae and 5-15 parts of pseudo-ginseng.
The technical effects described in the present invention can be achieved by the above technical solutions, and in some preferred embodiments, the achieved technical effects are superior to other solutions.
For example:
when the ratio of astragalus root, yam rhizome, phellodendron bark and notoginseng is 20-30:10-20:10-15:8-10 parts by weight of a preferred traditional Chinese medicine composition for treating kidney diseases, which comprises the following specific components in parts by weight: 5 parts of mistletoe, 10 parts of medlar, 5 parts of American ginseng, 20 parts of astragalus, 10 parts of yam rhizome, 10 parts of amur corktree bark, 10 parts of rhizoma anemarrhenae and 5 parts of pseudo-ginseng;
the traditional Chinese medicine composition for treating kidney diseases comprises the following specific components in parts by weight: 20 parts of mistletoe, 20 parts of medlar, 15 parts of American ginseng, 30 parts of astragalus, 20 parts of yam rhizome, 15 parts of amur corktree bark, 30 parts of rhizoma anemarrhenae and 15 parts of pseudo-ginseng;
optimally, the traditional Chinese medicine composition for treating kidney diseases comprises the following specific components in parts by weight: 10 parts of mistletoe, 12 parts of medlar, 6 parts of American ginseng, 30 parts of astragalus, 15 parts of yam rhizome, 12 parts of amur corktree bark, 12 parts of common anemarrhena rhizome and 9 parts of sanchi.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating kidney diseases, which comprises the following steps: pulverizing the raw materials of the traditional Chinese medicine composition with the formula amount to obtain the traditional Chinese medicine composition.
The invention also provides a traditional Chinese medicine extract for treating kidney diseases, which is prepared by extracting the traditional Chinese medicine composition.
Preferably, the extraction is at least one of water decoction, immersion, percolation, modified gelatin, reflux, solvent extraction, steam distillation, sublimation, supercritical fluid extraction, membrane separation, superfine pulverizing, flocculation separation, semi-bionic extraction, ultrasonic extraction, cyclone extraction, pressurized countercurrent extraction, enzyme, macroporous resin adsorption, ultrafiltration and molecular distillation.
The invention also provides a preparation method of the traditional Chinese medicine extract for treating kidney diseases, which comprises the following steps:
s1, crushing the raw materials of the traditional Chinese medicine composition with the formula amount to obtain fine powder;
s2, adding water into the fine powder obtained in the step S1 for extraction to obtain an extracting solution;
s3, concentrating the extracting solution obtained in the step S2 under reduced pressure to obtain the traditional Chinese medicine composition.
Preferably, the pulverization in step S1 is carried out to a particle size of 50 to 350. Mu.m.
Preferably, the mass ratio of the fine powder to the water in the step S2 is 1:15-19.
Preferably, the conditions of the extraction in step S2 are: extracting in water bath at 98-100deg.C for 5-8 hr.
The invention also provides application of the traditional Chinese medicine composition and/or the traditional Chinese medicine extract in preparation of preparations for treating kidney diseases.
The invention also provides a preparation for treating the kidney disease, which comprises the traditional Chinese medicine composition and/or the traditional Chinese medicine extract for treating the kidney disease and medically acceptable auxiliary materials.
Preferably, the dosage form of the formulation includes, but is not limited to, granules, pills, tablets, powders, ointments, oral liquids, suspensions or capsules.
The beneficial effects of the invention are as follows:
under the guidance of the theory of liver regulating, pivot eliminating and turbidity eliminating method, the Chinese medicinal composition disclosed by the invention is prepared by carefully selecting and combining eight Chinese medicaments including mistletoe, medlar, american ginseng, astragalus, yam rhizome, phellodendron bark, rhizoma anemarrhenae and pseudo-ginseng, and surprisingly discovered that the four raw materials including astragalus, yam rhizome, phellodendron bark and pseudo-ginseng are utilized to synergistically increase the functions of resisting inflammation and preventing and treating kidney fibrosis, thereby playing the roles of protecting kidney and delaying the progress of kidney diseases, and remarkably improving the clinical symptoms and manifestations of common kidney diseases such as acute and chronic nephritis, chronic nephrosis and renal failure, and the like, and is safe and free from toxic and side effects.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The invention does not limit the sources of the adopted raw materials, and if no special description exists, the adopted raw materials are all common commercial products in the technical field. The yam rhizome in the invention can be yam rhizome, yam rhizome or yam rhizome, and has no influence on the appearance of technical effect. Evaluation of Effect of Chinese medicinal composition on renal fibrosis
1 Experimental materials
1.1 laboratory animals
Adult male mice were selected and weighing 18-22g, 56 total, purchased from the medical laboratory animal center in Guangdong province.
1.2 laboratory apparatus, instruments and consumables
TABLE 1
1.3 Experimental reagents
TABLE 2
2 principle of experiment
Unilateral ureteral ligation (UUO) has been widely used to model kidney fibrosis in animals. Kidneys on the ligature side of the ureter gradually develop tubular dilation over time, and inflammatory cell infiltration and extracellular matrix (ECM) accumulation are characterized by activated fibroblasts expressing α -SMA, commonly referred to as myofibroblasts, which produce extracellular matrix, critical to the effects of renal fibrosis. The experiment is carried out by using a uuo day animal model to judge whether the traditional Chinese medicine composition has a therapeutic effect on renal fibrosis.
3 Experimental method
3.1 construction of renal fibrosis model
UFO modeling was performed according to literature report methods to construct kidney fibrosis models.
The specific operation flow is briefly described as follows C 57 BL/6 mice were induced and maintained under anesthesia by isoflurane/oxygen inhalation, then supine fixed on a temperature controlled operating table, shaved, and sterilized with iodine, 75% alcohol, and a ventral midlineThe skin is sequentially cut to the abdominal cavity by the longitudinal incision, the left kidney is exposed, the left ureter is blunted, the ligation is performed on the lower pole of the left kidney by using a 4-0 wire, the ureter is not cut off, the ureter is still in situ, and the abdominal incision is sutured layer by layer. The sham group only separated the left ureter and did not ligate the ureter.
3.2 grouping and administration of animals
56 mice were randomly divided into 7 groups according to body weight according to a random number table method, namely a sham operation group (Ctrl), a UUO Model group (Model) and a UUO+traditional Chinese medicine combination group T1-5 (administration dose of 0.455 g/kg/d), and the Ctrl group and the Model group were given equal volumes of distilled water. Model preparation was given by intragastric administration or distilled water for 7 days on the same day.
Wherein, the traditional Chinese medicine composition (T-1) consists of 10 parts by weight of mistletoe, 12 parts by weight of medlar, 6 parts by weight of American ginseng, 30 parts by weight of astragalus, 15 parts by weight of yam rhizome, 12 parts by weight of amur corktree bark, 12 parts by weight of rhizoma anemarrhenae and 9 parts by weight of pseudo-ginseng.
The traditional Chinese medicine composition (T-2) comprises, by weight, 5 parts of Chinese taxillus twig, 10 parts of medlar, 5 parts of American ginseng, 20 parts of astragalus, 10 parts of yam rhizome, 10 parts of amur corktree bark, 10 parts of rhizoma anemarrhenae and 5 parts of pseudo-ginseng.
The traditional Chinese medicine composition (T-3) comprises, by weight, 20 parts of mistletoe, 20 parts of wolfberry fruit, 15 parts of American ginseng, 30 parts of astragalus, 20 parts of yam rhizome, 15 parts of phellodendron, 30 parts of rhizoma anemarrhenae and 15 parts of pseudo-ginseng.
The traditional Chinese medicine composition (T-4) comprises, by weight, 10 parts of mistletoe, 12 parts of medlar, 6 parts of American ginseng, 35 parts of astragalus, 22 parts of yam rhizome, 4 parts of phellodendron, 12 parts of rhizoma anemarrhenae and 4 parts of pseudo-ginseng.
The traditional Chinese medicine composition (T-5) comprises, by weight, 10 parts of Chinese taxillus twig, 12 parts of medlar, 6 parts of American ginseng, 18 parts of astragalus, 8 parts of yam rhizome, 18 parts of amur corktree bark, 12 parts of rhizoma anemarrhenae and 15 parts of pseudo-ginseng.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
s1, crushing the raw materials of the traditional Chinese medicine composition with the formula amount to obtain fine powder with the particle size of 300 mu m;
s2, adding water into the fine powder obtained in the step S1 according to the feed-liquid ratio (mass ratio) of 1:17, and extracting in a water bath at 100 ℃ for 6 hours to obtain an extracting solution;
s3, concentrating the extracting solution obtained in the step S2 under reduced pressure, and drying.
3.3 sample collection
After the last administration, mice were induced and maintained under anesthesia by isoflurane/oxygen inhalation, kidney tissue was taken from the side of obstruction, renal capsule was removed, the coronal plane was cut open to kidney tissue, half was fixed with 4% polyaldehyde, and the other half was placed in EP tube and frozen in-80 ℃ refrigerator.
4 detection index
4.1 RNA extraction from kidney tissue and real-time fluorescence PCR (qRT-PCR)
Taking a proper amount of kidney tissue in a 1.5mL enzyme-removing EP tube, adding 500 mu L of Trizol and 2 grinding beads, placing in a homogenizer for homogenization treatment, standing on ice for 15min, adding 50 mu L of chloroform, shaking vigorously, standing on ice for 5min, centrifuging at 12000rpm/min for 8min, carefully sucking the supernatant, adding equal amount of ice isopropanol, mixing uniformly, standing on ice for 10min, centrifuging at 12000rpm/min for 15min, and discarding the supernatant to obtain RNA precipitate. And (5) cleaning the precipitate with 75% ethanol, and then placing the precipitate on an ultra-clean bench for airing. Adding 10-20uLDEPC water into each tube to dissolve and precipitate, measuring RNA concentration by using a Nanodrop one ultramicro nucleic acid quantitative instrument, and freezing in a refrigerator at-80 ℃.
The volume required for 1500. Mu.g RNA was calculated, and a 20. Mu.L system was prepared and reverse transcribed into cDNA according to EZB kit procedures.
TABLE 3 RNA reverse transcription System
The reaction procedure: reacting for 15 minutes at 42 ℃ and 30 seconds at 95 ℃, and obtaining a product after the reaction is finished, namely the cDNA. Real-time fluorescent quantitative PCR was performed using EZB kit using 15. Mu.L reaction system.
Table 4 real-time fluorescent quantitative PCR reaction system
After the system is prepared, PCR amplification is carried out, and the amplification reaction program is set as follows:
mRNA expression levels of alpha-SMA and collagenI in kidney tissues were detected. The primer sequences were as follows:
TABLE 5
4.2 renal tissue pathology
Left kidney tissue fixation, dehydration, embedding, and sectioning: kidney tissue is obtained and then is put into a tissue embedding box, and is soaked in 4% paraformaldehyde for fixation. And (5) carrying out gradient dehydration in an automatic dehydrator after 72 h. After dehydration, paraffin embedding is carried out by an embedding machine. Slicing the embedded paraffin with a slicer to obtain 4 μm thick paraffin, fixing on a glass slide, oven drying, and storing in a slicing box.
IHC staining: (1) the sections were placed in a 60 ℃ oven for dewaxing for 1 hour and in a fume hood, dewaxing was performed sequentially: 10min of dimethylbenzene, 5min of absolute ethyl alcohol, 5min of 95% ethyl alcohol, 5min of 85% ethyl alcohol, 5min of 75% ethyl alcohol and 2min of double distilled water. Preheating 0.1M citric acid antigen retrieval liquid (92-98 ℃) in advance, placing the slices in buffer solution, heating with high fire in a microwave oven for 20min, cooling at room temperature, placing an immunohistochemical pen on a wet dressing box arranged behind a tissue peripheral drawing ring, and adding a proper amount of 3%H into the tissue 2 O 2 Washing for 10min, and throwing away 3%H 2 O 2 The mixture was washed 3 times with 0.02% PBST, 5 min/time, 5% goat serum, blocked at room temperature for 30min, blocking solution was discarded, a-SMA primary antibody was incubated, and incubated overnight at 4 ℃. Discarding primary antibody, washing 3 times with 0.02% PBST for 5 min/time, incubating secondary antibody containing HRP, discarding secondary antibody at room temperature for 1h, washing 3 times with 0.02% PBST for 5 min/time, developing DAB for 2min, immediately washing with double distilled water, hematoxylin dying core for 11s, and washing with running water for 2min.95% ethanol for 2min, absolute ethanol for 2min, xylene for 2min, and neutral resin sealing. Observation under microscopeShooting.
4.3 data processing and statistical analysis
The data are subjected to statistical analysis by adopting SPSS25.0 software, experimental data results are expressed by mean + -standard error (mean + -SEM), and statistics is carried out by a pairwise comparison method of the mean between a plurality of experimental groups and a control group; proper variable conversion is carried out on the data with non-normal or variance, and statistics is carried out on the converted data after the normal or variance alignment requirement is met; if the normal or variance alignment purpose is not achieved after the variable conversion, the rank sum test is used for statistics. P <0.05 was considered statistically different.
5 experimental results
5.1 renal tissue fibrosis mRNA levels
TABLE 6 variation of mRNA levels of kidney tissue fibrotic alpha-SMA
| Group of | n | mRNA of alpha-SMA | P |
| Ctrl | 5 | 1±0.848 | - |
| Model | 3 | 3.545±1.406 | 0.028 |
| T-1 | 6 | 0.766±0.668 | 0.017 |
| T-2 | 5 | 1.226±0.859 | 0.046 |
| T-3 | 5 | 1.149±0.938 | 0.032 |
| T-4 | 6 | 2.113±0.880 | 0.131 |
| T-5 | 6 | 2.050±0.470 | 0.080 |
As can be seen from table 6, the mRNA levels of α -SMA for Model group were significantly different from Ctrl group; meanwhile, compared with a Model group, the mRNA levels of the alpha-SMA in the T-1, T-2 and T-3 groups are obviously different, and P is smaller than 0.05, so that the traditional Chinese medicine composition prepared by the invention can inhibit the expression of the mRNA of the alpha-SMA and has the effect of treating kidney fibrosis.
Compared with the Model group, the mRNA level of the alpha-SMA in the T-4 and T-5 groups has no statistical significance, and P is more than 0.05, which shows that when the mass ratio of the four components of astragalus, yam rhizome, phellodendron and pseudo-ginseng in the formula is changed, the prepared traditional Chinese medicine composition does not have the effect of treating kidney fibrosis.
TABLE 7 variation of mRNA levels of renal tissue fibrosis collagenI
| Group of | n | mRNA of collagenI | P |
| Ctrl | 5 | 1±1.398 | - |
| Model | 5 | 14.164±6.910 | 0.0057 |
| T-1 | 6 | 5.804±2.896 | 0.0376 |
| T-2 | 7 | 7.310±2.139 | 0.0482 |
| T-3 | 7 | 6.722±3.366 | 0.0479 |
| T-4 | 7 | 8.279±5.935 | 0.180 |
| T-5 | 7 | 9.708±5.627 | 0.288 |
As can be seen from Table 7, the mRNA levels of collagenI in the Model group were very significantly different, P <0.05, compared to that in the Ctrl group; meanwhile, compared with a Model group, the mRNA levels of the collgen I in the T-1, T-2 and T-3 groups are obviously different, and P is smaller than 0.05, so that the traditional Chinese medicine composition prepared by the invention can inhibit the expression of the mRNA of the collgen I and has the effect of treating kidney fibrosis.
Compared with the Model group, the mRNA level of collagen I in the T-4 and T-5 groups has no statistical significance, and P is more than 0.05, which indicates that when the mass ratio of four of astragalus, yam rhizome, phellodendron and pseudo-ginseng in the formula is changed, the prepared traditional Chinese medicine composition does not have the effect of treating kidney fibrosis.
Remarks: the data of Ctrl group in tables 6 and 7 are normalized results.
In summary, under the guidance of the theory of liver regulating, liver activating and turbidity resolving method, the Chinese medicinal composition disclosed by the invention is prepared by carefully selecting eight Chinese medicaments including mistletoe, medlar, american ginseng, astragalus, yam rhizome, phellodendron bark, rhizoma anemarrhenae and pseudo-ginseng, and surprisingly, the effects of protecting kidney and delaying the progress of kidney diseases are achieved by utilizing the synergistic interaction of four raw materials including astragalus, yam rhizome, phellodendron bark and pseudo-ginseng, and the Chinese medicinal composition has the effects of protecting kidney and delaying the progress of kidney diseases through anti-inflammatory treatment, and the clinical symptoms of common kidney diseases such as acute and chronic nephritis, chronic kidney disease and renal failure are obviously improved, and the Chinese medicinal composition is safe and has no toxic or side effect.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating the kidney disease is characterized by comprising the following components in parts by weight: 5-20 parts of mistletoe, 10-20 parts of medlar, 5-15 parts of American ginseng, 10-30 parts of astragalus, 5-20 parts of yam rhizome, 5-15 parts of amur corktree bark, 10-30 parts of rhizoma anemarrhenae and 5-15 parts of pseudo-ginseng;
and the weight ratio of the astragalus, the yam rhizome, the amur corktree bark and the sanchi is 20-30:10-20:10-15:8-10.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 10 parts of mistletoe, 12 parts of medlar, 6 parts of American ginseng, 30 parts of astragalus, 15 parts of yam rhizome, 12 parts of amur corktree bark, 12 parts of common anemarrhena rhizome and 9 parts of sanchi.
3. The method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 2, comprising the following steps: pulverizing the raw materials of the traditional Chinese medicine composition with the formula amount to obtain the traditional Chinese medicine composition.
4. Use of the traditional Chinese medicine composition according to any one of claims 1-2 in the preparation of a medicament for treating kidney diseases.
5. A medicament for treating kidney diseases, which is characterized by comprising the traditional Chinese medicine composition according to any one of claims 1-2 and pharmaceutically acceptable auxiliary materials.
6. The medicament according to claim 5, wherein the medicament is in the form of granules, pills, tablets, powders, ointments, oral liquids, suspensions or capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210947482.6A CN115282232B (en) | 2022-08-09 | 2022-08-09 | Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210947482.6A CN115282232B (en) | 2022-08-09 | 2022-08-09 | Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115282232A CN115282232A (en) | 2022-11-04 |
| CN115282232B true CN115282232B (en) | 2023-11-10 |
Family
ID=83827284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210947482.6A Active CN115282232B (en) | 2022-08-09 | 2022-08-09 | Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115282232B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107684611A (en) * | 2016-08-03 | 2018-02-13 | 刘玉宽 | It is a kind of to be used to treat Chinese medicine of ephritis, renal failure and preparation method thereof |
| CN111375022A (en) * | 2020-06-02 | 2020-07-07 | 中国药科大学 | Traditional Chinese medicine composition for treating prostatic hyperplasia |
-
2022
- 2022-08-09 CN CN202210947482.6A patent/CN115282232B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107684611A (en) * | 2016-08-03 | 2018-02-13 | 刘玉宽 | It is a kind of to be used to treat Chinese medicine of ephritis, renal failure and preparation method thereof |
| CN111375022A (en) * | 2020-06-02 | 2020-07-07 | 中国药科大学 | Traditional Chinese medicine composition for treating prostatic hyperplasia |
Non-Patent Citations (4)
| Title |
|---|
| 丁樱教授治疗小儿肾病综合征经验撷菁;黄芳;吴磊;丁樱;;光明中医;-;第-卷(第04期);第631-632页 * |
| 中西医结合治疗肾病综合征50例;吴亮;甘肃中医;-;第-卷(第03期);第24页3. 中医辨证治疗 * |
| 沈丕安.《中药药理与临床运用 下》.《中药药理与临床运用 下》.吉林科学技术出版社,2020,第701页. * |
| 自拟五物补肾汤治疗慢性肾炎68例;朱迪海;;浙江中医杂志;-;第-卷(第04期);第216页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115282232A (en) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687994B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
| Meng et al. | From Xiaoke to diabetes mellitus: a review of the research progress in traditional Chinese medicine for diabetes mellitus treatment | |
| WO2021179902A1 (en) | Use of corydalis saxicola and preparation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| CN102988675A (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN115282232B (en) | Traditional Chinese medicine composition for treating kidney diseases, extract, preparation method, application and preparation | |
| CN100471865C (en) | Process for preparing notoginseng diol saponin | |
| CN105434915A (en) | Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition | |
| CN107669726A (en) | Treat the wormwood extract liniment of eczema | |
| CN111407783B (en) | Application of penthorum chinense pursh in preparation of medicine for treating high proteinuria | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN114558094A (en) | Sanqi dampness eliminating formula and application thereof | |
| CN107050359B (en) | Zhuang medicine preparation for treating sequelae of chronic pelvic inflammatory disease and preparation method thereof | |
| CN105477361A (en) | Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN103933386A (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN112386671B (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof | |
| CN114470144B (en) | Prostate eliminating soup for inhibiting prostate fibrosis and preparation method thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN115501280B (en) | Traditional Chinese medicine composition for improving fatty liver as well as preparation method, extract, application and preparation thereof | |
| CN104815194A (en) | Method for preparing medicine for treating diabetic nephropathy | |
| CN102233084A (en) | Chinese medicinal composition for treating prostatitis and preparation method thereof | |
| CN111249421B (en) | Traditional Chinese medicine preparation for treating initial damp-heat exogenous fever as well as preparation method and application thereof | |
| CN109939176B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN117771342A (en) | Traditional Chinese medicine composition for treating ulcerative colitis, preparation method and application | |
| CN114470019A (en) | Application of radix araliae armatae extract in preparation of medicine for preventing and/or treating proteinuria and related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |